-
MaaT013 Achieves Primary Endpoint in ARES Trial for GI-aGVHD
16 Jan 2025 15:19 GMT
… face an urgent unmet medical need with alarmingly low … 3 trial represent a groundbreaking advancement in third-line treatment for … therapy with oral vancomycin (Vancocin) at a dose of … Pittari, MD, PhD, chief medical officer of MaaT Pharma, added …
-
ARES Trial of MaaT013 in Acute GVHD Meets Primary End Point
13 Jan 2025 14:39 GMT
… trial assessing MaaT013 in the third-line setting following treatment … face an urgent unmet medical need with alarmingly low … pretreatment with oral vancomycin (Vancocin) at a dose of … Authorization Application to the European Medicines Agency by mid-2025, …
-
ARES Trial of MaaT013 in GI-aGVHD Meets Primary End Point of GI-ORR
09 Jan 2025 19:54 GMT
… face an urgent unmet medical need with alarmingly low … 3 trial represent a groundbreaking advancement in third-line treatment for … therapy with oral vancomycin (Vancocin) at a dose of … Pittari, MD, PhD, chief medical officer of MaaT Pharma, added …
-
July - September 2019 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)
16 Sep 2024 17:01 GMT
…
Kisqali label
Verzenio label
FDA Drug Safety Communication
Elmiron (pentosan … labeling
Firvanq (vancomycin hydrochloride)
Vancocin (vancomycin hydrochloride)
Generic products … bullous dermatosis (LABD)].
Vancocin labeling
Firvanq labeling
Fluoroquinolones
…
-
Acurx Pharma presents ibezapolstat phase 2 trial results for CDI at scientific conference
16 Jul 2024 12:57 GMT
Acurx Pharmaceuticals, Inc. a … rate of approximately 81% (Vancocin Prescribing Information, January 2021), … in consultation with its medical and scientific advisors … Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment …
-
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection
16 May 2024 07:49 GMT
… Drug Administration (FDA), supporting the advancement of ibezapolstat for the treatment … approximately 81% (Vancocin® Prescribing … its medical and … trial results and previously reported (CID, 2022).
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals …
-
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference
03 May 2024 05:40 GMT
… approximately 81% (Vancocin® Prescribing … its medical and … Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment … trial results and previously reported (CID, 2022).
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals …
-
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
25 Apr 2024 18:48 GMT
… approximately 81% (Vancocin® Prescribing … its medical and … Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment … trial results and previously reported (CID, 2022).
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals …
-
Acurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Development
28 Feb 2024 06:57 GMT
… FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment … treatment. There were no drug-related treatment … 81% (Vancocin® … trial results and previously reported (CID, 2022).
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals …
-
Vancomycin (Vancocin) and cost
25 Jan 2024 17:52 GMT
… ) infusion
The Food and Drug Administration (FDA) has approved Vancomycin oral capsule … the brand-name drugs Vancocin and Firvanq. If your doctor has prescribed vancomycin … medication is covered. If a drug requires prior authorization but you start treatment …
About
© 1995-2025